Investor's Business Daily on MSN
Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook
Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.
Abstract: In this paper we consider a scheduling problem where a set of jobs are simultaneously available for processing in a no-wait two-machine flowshop. All jobs are processed on both machines in ...
A groundbreaking new tool created by an international team of scientists could help doctors spot people at higher risk for ...
Abstract: Presently, there is a significant decrease in the availability of fossils as a source of primary energy due to the continuous usage, time and constraints of environmental pollution. This led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results